RU2012125186A - Месаламиновый суппозиторий - Google Patents

Месаламиновый суппозиторий Download PDF

Info

Publication number
RU2012125186A
RU2012125186A RU2012125186/15A RU2012125186A RU2012125186A RU 2012125186 A RU2012125186 A RU 2012125186A RU 2012125186/15 A RU2012125186/15 A RU 2012125186/15A RU 2012125186 A RU2012125186 A RU 2012125186A RU 2012125186 A RU2012125186 A RU 2012125186A
Authority
RU
Russia
Prior art keywords
mesalamine
suppository
dissolution
particles
range
Prior art date
Application number
RU2012125186/15A
Other languages
English (en)
Russian (ru)
Inventor
Ив ДЮМУЛЕН
Карл ГОТЬЕ
Хью МОРО
Дэвид Пауэлл
Original Assignee
Апталис Фарма Кэнэда Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43901620&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RU2012125186(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Апталис Фарма Кэнэда Инк. filed Critical Апталис Фарма Кэнэда Инк.
Publication of RU2012125186A publication Critical patent/RU2012125186A/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/606—Salicylic acid; Derivatives thereof having amino groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
RU2012125186/15A 2009-12-16 2010-12-16 Месаламиновый суппозиторий RU2012125186A (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12/639,645 2009-12-16
US12/639,645 US8436051B2 (en) 2007-06-08 2009-12-16 Mesalamine suppository
PCT/US2010/060849 WO2011084638A2 (en) 2009-12-16 2010-12-16 Mesalamine suppository

Publications (1)

Publication Number Publication Date
RU2012125186A true RU2012125186A (ru) 2014-01-27

Family

ID=43901620

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2012125186/15A RU2012125186A (ru) 2009-12-16 2010-12-16 Месаламиновый суппозиторий

Country Status (14)

Country Link
US (2) US8436051B2 (enExample)
EP (1) EP2512443A2 (enExample)
JP (1) JP2013514979A (enExample)
KR (1) KR20120104604A (enExample)
CN (1) CN102970971A (enExample)
AU (1) AU2010339837A1 (enExample)
CA (2) CA2690450A1 (enExample)
CL (1) CL2012001636A1 (enExample)
IL (1) IL220397A0 (enExample)
MX (1) MX2012006902A (enExample)
RU (1) RU2012125186A (enExample)
SG (1) SG181169A1 (enExample)
WO (1) WO2011084638A2 (enExample)
ZA (1) ZA201204422B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8436051B2 (en) 2007-06-08 2013-05-07 Aptalis Pharma Canada Inc. Mesalamine suppository
ES2377225T3 (es) 2008-09-19 2012-03-23 OERLIKON TRADING AG, TRÜBBACH Método para producir capas de óxido metálico mediante vaporización por arco
CN103153944A (zh) * 2010-09-10 2013-06-12 法莫再尔公司 晶态5-氨基水杨酸的制备方法
WO2013059768A1 (en) * 2011-10-20 2013-04-25 Aptalis Pharma U.S., Inc. Therapeutic agents for treating gastrointestinal disorders associated with inflammation of the gastrointestinal tract
CN103622974B (zh) * 2013-12-05 2016-04-20 武汉武药科技有限公司 一种含美沙拉嗪和n-乙酰半胱氨酸的复方栓剂及其制备方法
US20160175271A1 (en) * 2014-12-19 2016-06-23 Gavis Pharmaceuticals Rectal suppository for ulcerative colitis
US10098898B1 (en) 2017-12-04 2018-10-16 Handa Pharmaceuticals, Llc Release stable mesalamine dosage forms
AR120360A1 (es) * 2019-10-31 2022-02-09 Scherer Technologies Llc R P Cápsula de supositorio
KR20250042058A (ko) 2023-09-19 2025-03-26 한양대학교 산학협력단 염증성 장 질환 치료용 약학적 조성물

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3689514A (en) 1969-05-21 1972-09-05 Schlueter Edelfett Suppository vehicle and process of making same
US4211777A (en) 1977-11-25 1980-07-08 Fisons Limited Compositions comprising a compound having sodium cromoglycate activity and aminosalicylic acid
US4298595A (en) 1978-12-20 1981-11-03 Dynapol Pharmaceutical preparations containing a polymeric agent for releasing 5-aminosalicylic acid or its salts into the gastrointestinal tract
US4374932A (en) 1981-06-08 1983-02-22 G. D. Searle & Co. 5-ASA Drug delivery system
DE3151196A1 (de) 1981-12-23 1983-06-30 Kurt Heinz Prof. Dr. 7800 Freiburg Bauer Verfahren zur herstellung von gut loeslichen 5-aminosalicylsaeure-arzneimittelzubereitungen
JPH0816051B2 (ja) 1988-12-07 1996-02-21 エスエス製薬株式会社 徐放性坐剤
US5629012A (en) 1991-06-17 1997-05-13 Farmaceutisk Laboratorium Ferring A/S Process for producing suppositories by compression and suppositories obtained by the process
GB9201857D0 (en) 1992-01-29 1992-03-18 Smithkline Beecham Plc Novel compound
US5389375A (en) 1993-05-21 1995-02-14 University Of Mississippi Stable suppository formulations effecting bioavailability of Δ9 -thc
DK66493D0 (da) 1993-06-08 1993-06-08 Ferring A S Praeparater, isaer til brug ved behandling af inflammatoriske tarmsygdomme eller til at opnaa forbedret saarheling
WO1997009035A1 (en) 1995-09-07 1997-03-13 Taisho Pharmaceutical Co., Ltd. Long-lasting composition for rectal administration
JPH09323934A (ja) 1996-05-31 1997-12-16 Kanebo Ltd 保存安定性の改善された坐剤
WO1998043667A1 (en) 1997-04-01 1998-10-08 Borody Thomas J Methods and compositions for treating inflammatory bowel disease
ES2224428T3 (es) 1997-09-26 2005-03-01 Celltech Pharma Europe Limited Composicion farmnaceutica para el tratamiento de la enfermedad inflmatoria intestinal.
WO1999017737A1 (fr) 1997-10-08 1999-04-15 Taisho Pharmaceutical Co., Ltd. Composition de suppositoire
US6326364B1 (en) 1999-02-08 2001-12-04 Cedars-Sinai Medical Center Use of 5-aminosalicylates as antimicrobial agents
US6610674B1 (en) 1999-09-28 2003-08-26 University Of Pennsylvania Method of treating inflammatory conditions with progesterone analogs
US6720001B2 (en) 1999-10-18 2004-04-13 Lipocine, Inc. Emulsion compositions for polyfunctional active ingredients
US20020037855A1 (en) 2000-05-05 2002-03-28 Fritz Stanislaus Stabilized medicament containing cysteinyl derivatives
CA2420576C (en) 2000-08-29 2005-06-14 Nobex Corporation Immunoregulatory compounds, derivatives thereof and their use
US20060104946A1 (en) 2002-08-23 2006-05-18 Zymogenetics, Inc. Method for treating inflammatory bowel disease
US7312243B1 (en) 2003-08-29 2007-12-25 Jay Pravda Materials and methods for treatment of gastrointestinal disorders
US7825106B2 (en) 2003-09-03 2010-11-02 Agi Therapeutics Ltd. Modified release formulations and methods of treating inflammatory bowel disease
EP1722630A4 (en) 2004-01-20 2009-05-27 Richard F Harty COMPOSITIONS AND METHOD FOR THE TREATMENT OF INFLAMMATORY DISEASES
EP1751096A4 (en) 2004-05-27 2009-01-07 Antibe Therapeutics Inc 4- OR 5- AMINOSALICYLIC ACID SALT
CZ2004945A3 (cs) 2004-09-08 2006-01-11 Pliva - Lachema A. S. Farmaceutická kompozice pro rektální nebo vaginální podání, zpusob její prípravy a tato kompozice pro pouzití jako lécivo
US20080020018A1 (en) 2004-09-27 2008-01-24 Joey Moodley Combination Products
US7250445B1 (en) 2005-01-14 2007-07-31 Ehrenpreis Eli D Anti-oxidant suppository for treating radiation proctopathy and other anorectal disorders
US8921344B2 (en) 2006-11-03 2014-12-30 Salix Pharmaceuticals, Inc. Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives
AU2007223988A1 (en) 2006-03-07 2007-09-13 Zalicus Inc. Compositions and methods for the treatment of immunoinflammatory disorders
US20070240236A1 (en) 2006-04-05 2007-10-11 Oklahoma Medical Research Foundation O-glycans in the treatment of inflammatory bowel disease and cancers
US20070254050A1 (en) 2006-05-01 2007-11-01 Quart Barry D Method for treatment of diarrhea-predominant irritable bowel syndrome
JP2009535419A (ja) 2006-05-01 2009-10-01 ナポ ファーマシューティカルズ インク． 便秘型過敏性腸症候群の治療方法
US7842709B2 (en) 2006-09-08 2010-11-30 Ore Pharmaceuticals Inc. Method for treating inflammatory diseases of the digestive tract
US8217083B2 (en) * 2007-06-08 2012-07-10 Aptalis Pharma Canada Inc. Mesalamine suppository
US7541384B2 (en) * 2007-06-08 2009-06-02 Axcan Pharma Inc. Mesalamine suppository
US8436051B2 (en) 2007-06-08 2013-05-07 Aptalis Pharma Canada Inc. Mesalamine suppository

Also Published As

Publication number Publication date
CA2690450A1 (en) 2011-06-16
WO2011084638A3 (en) 2012-04-05
US20130231310A1 (en) 2013-09-05
SG181169A1 (en) 2012-07-30
US20100105639A1 (en) 2010-04-29
US8436051B2 (en) 2013-05-07
EP2512443A2 (en) 2012-10-24
JP2013514979A (ja) 2013-05-02
MX2012006902A (es) 2012-10-05
CN102970971A (zh) 2013-03-13
AU2010339837A1 (en) 2012-06-28
US9884018B2 (en) 2018-02-06
WO2011084638A2 (en) 2011-07-14
IL220397A0 (en) 2012-08-30
CA2784772A1 (en) 2011-07-14
CL2012001636A1 (es) 2012-10-12
KR20120104604A (ko) 2012-09-21
ZA201204422B (en) 2013-08-28

Similar Documents

Publication Publication Date Title
RU2012125186A (ru) Месаламиновый суппозиторий
ES2830033T3 (es) Composiciones de solución sólida y uso en enfermedad cardiovascular
JP7070977B2 (ja) 癌、自己免疫障害、及び慢性炎症に関連する他の病態の治療方法
US20240277613A1 (en) Solid Solution Compositions and Use in Chronic Inflammation
JP2014514349A5 (enExample)
RU2015104537A (ru) Способы лечения стромальных опухолей желудочно-кишечного тракта
MA34771B1 (fr) Formes cristallines
RU2013109138A (ru) ЛЕКАРСТВЕННАЯ ДОЗИРОВАННАЯ ФОРМА, КОТОРАЯ СОДЕРЖИТ 6'-ФТОР-(N-МЕТИЛ-ИЛИ N,N-ДИМЕТИЛ-)-4-ФЕНИЛ-4',9'-ДИГИДРО-3'Н-СПИРО[ЦИКЛОГЕКСАН-1,1'-ПИРАНО[3,4,b]ИНДОЛ]-4-АМИН
JP2013514979A5 (enExample)
EA200800147A1 (ru) Способ получения олмесартан медоксомила
EA201390840A1 (ru) Полициклический lpaантагонист и его применение
JP2010525033A5 (enExample)
JP2002509103A (ja) 経口液体組成物
EA201000268A1 (ru) Производные n-(ариламино)сульфонамидов, включая полиморфы, в качестве ингибиторов mek, а также композиции, способы применения и способы их приготовления
RU2009136669A (ru) Лечение меланомы
RU2012121630A (ru) АЛЛОСТЕРИЧЕСКИЕ СРЕДСТВА ПОТЕНЦИРОВАНИЯ mGluR4 КОМПОЗИЦИИ И СПОСОБЫ ЛЕЧЕНИЯ НЕВРОЛОГИЧЕСКИХ ДИСФУНКЦИЙ
RU2011105810A (ru) Азотсодержащие бициклические гетероциклические соединения
RU2007146395A (ru) Диспергируемые таблетки бозентана
RU2005137571A (ru) Новые производные диазабициклононена
Cui et al. Chloroquine inhibits NLRP3 inflammasomes activation and alleviates renal fibrosis in mouse model of hyperuricemic nephropathy with aggravation by a high-fat-diet
JP2015505550A5 (enExample)
JP2008543836A5 (enExample)
RU2007138582A (ru) Пероральные дозированные формы производных гемцитабина
CN1897932A (zh) 含有芹菜素作为软骨再生剂用于治疗骨关节炎的组合物
EP3981391A4 (en) ORAL PREPARATION WITH IMPROVED DISSOLUTION RATE AND DEGRADATION PROPERTIES FOR NATURAL PRODUCT EXTRACT

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20150225